Abstract: Disclosed herein are technologies for remote debugging in mobile web applications using a platform-independent debugging proxy server. Particularly, the debugging proxy server acts as an intermediary by fetching and performing instrumentation on a requested webpage by a target browser. This Abstract is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.

Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.

Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways.

Abstract: Use of cell-substrate impedance based methods for screening for agonists of G-Protein Coupled Receptors (GPCRs) or inhibitors of a Receptor Tyrosine Kinases (RTKs), identifying compounds that affect GPCR or RTK pathways, validating molecular targets involved in a GPCR or RTK signaling pathways, monitoring dose-dependent functional activation of GPCR or RTK; determining desensitization of a GPCR and identifying a compound capable of affecting RTK activity in cancer cell proliferation.

Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.

Abstract: The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, and in some embodiments diseases or disorders related to the dysregulation of kinase such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, FLT3(D835Y), ITK, TEC, TXK, BTK, or JAK, and the respective pathways.

Abstract: The present invention includes devices and methods for transfecting a cell or cell population and dynamic monitoring of cellular events. A variety of microelectronic devices are provide that incorporate functions such as electroporation, modulation of a transmembrane potential and dynamic monitoring of cellular functions and mechanisms.

Abstract: Methods for identifying a compound capable of interacting with a Receptor Tyrosine Kinase (RTK) including providing a device capable of measuring cell-substrate impedance, adding test cells expressing a RTK to the device, measuring first impedances, adding a compound to at least one compound well and adding a vehicle control to at least one control well, measuring second impedances of the compound well and the control well, determining the change in the impedance for the compound well and the one control well, comparing the change in impedance between the compound well and the control well, and identifying the compound interacts with the RTK if the comparison demonstrates a significant difference between the change in impedance.

Abstract: A method, a system and a base-station for automatically determining delays of data transmitted via Transmission Control Protocol (TCP) and inflating these delays in order to reduce jitter and improve TCP throughput in a communications network. A Dynamic Jitter Reduction (DJR) logic/utility operating within a communications node measures delays on a rolling basis in order to capture the delay profile. Based on the delay profile, the DJR utility determines a delay target. The DJR utility ‘inflates’/augments future/expected delays toward the delay target by performing on one or more of the following: (a) using a delay based factor in the scheduler metric for TCP applications; (b) performing fine-tuning of link adaptation schemes; (c) delaying transmission of packets at the transmit or receive buffer; and (d) delaying transmission of a received TCP ACK signal from the media access control (MAC) sub-layer to TCP layer.

Abstract: Devices, systems and methods for monitoring excitable cells, such as cardiomyocytes, on microelectrode arrays that couple the electro-stimulation of excitable cells to induce or regulate cardiomyocyte beating and the simultaneous measurement of impedance and extracellular recording to assess changes in cardiomyocyte beating, viability, morphology or electrophysical properties in response to a plurality of treatments.

Abstract: Tricylic ether carbamates that inhibit HIV proteolytic enzymes and processes for preparing the compounds are describes. Methods of using the disclosed compounds for treating patients infected with HIV are also described.

Abstract: A method for value-added usage of process-oriented extension fields in business mashups may include generating, using at least one processor, a mashup component with m unbound parameter; receiving input identifying the creation of an extension field, the extension field tied to data stored in a database; binding the unbound parameter of the mashup component to the extension field: presenting an application interlace, the application interface including the extension field; receiving a request to load tee mashup component; and in response to receiving the request passing the data tied to the extension field as an input parameter to the mashup component.

Abstract: A method to secure html JavaScript code snippet usage in application integration may include serving a webpage accessible at a first domain to a user device. The webpage may include content hosted at the first domain a container for isolated execution of at least one mashup application. The at least one mashup application may be executed on a second domain. A request may be received at the first domain to render a mashup application. The mashup application may include code to display a combination of both business object data and third-party web service data. In response to the request, the mashup application may be transmitted from the first domain to the second domain. The mashup application may be served from the second domain in the container portion of the webpage of the first domain.

Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.

Abstract: Techniques and configurations for establishing cross-domain communications between a business application, a third party website or service, and mashup components of a mashup user interface are generally described herein. In one example embodiment, a scripting library which establishes socket connections between domains and between components of a common mashup user interface is included or referenced in a mashup component and in a third party component that are displayed in the common browser-based mashup user interface. A scripting library executing in the browser may be used to establish and control the socket connections that communicate changes to the business application data, transmitted from the third party webpage to the mashup. The changes to the business application data, communicated and received in front-end objects, then may be processed or further communicated for persistence at the business application.

Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.

Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.

Abstract: Iterating an optical phase conjugation of ultrasonically-modulated diffuse light emitted by a scattering medium includes illuminating the scattering medium with a light beam from a coherent light source, modulating the diffuse light transmitted through the scattering medium with an ultrasonic wave focused on a region of interest within the scattering medium, fixing a hologram, retro-reflectively illuminating the scattering medium using a phase-conjugated copy of the diffuse light that was ultrasonically modulated, moving the ultrasonic focus, and iterating until light is focused on the final target.

Abstract: Tricylic ether carbamates that inhibit HIV proteolytic enzymes and processes for preparing the compounds are described. Methods of using the disclosed compounds for treating patients infected with HIV are also described.

Abstract: One embodiment of the invention includes regulation voltage system for a power supply system. The system includes a current sense system configured to generate a sense signal that represents an output current of the power supply system that is supplied to a load. The system also includes a positive voltage droop controller configured to provide a regulation voltage to the power supply system, the positive voltage droop controller setting the regulation voltage to one of a predetermined fixed reference voltage or a variable reference voltage based on the sense signal. The variable reference voltage can be less than the predetermined fixed reference voltage.